These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38022442)

  • 1. Effect of Pranayama as Adjuvant to Medical Treatment on Severity, Frequency, and Duration of Headache in Migraine Patients: An Open-Label Randomized Controlled Trial.
    Kaushal A; Padam A; Sharma M; Sharma S
    Ann Indian Acad Neurol; 2023; 26(5):690-696. PubMed ID: 38022442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
    McAllister P; Cohen JM; Campos VR; Ning X; Janka L; Barash S
    J Headache Pain; 2022 Aug; 23(1):112. PubMed ID: 36038833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of yoga as add-on therapy in migraine (CONTAIN): A randomized clinical trial.
    Kumar A; Bhatia R; Sharma G; Dhanlika D; Vishnubhatla S; Singh RK; Dash D; Tripathi M; Srivastava MVP
    Neurology; 2020 May; 94(21):e2203-e2212. PubMed ID: 32376640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Soft Tissue Techniques on Headache Impact, Disability, and Quality of Life in Migraine Sufferers: A Pilot Study.
    Espí-López GV; Ruescas-Nicolau MA; Nova-Redondo C; Benítez-Martínez JC; Dugailly PM; Falla D
    J Altern Complement Med; 2018 Nov; 24(11):1099-1107. PubMed ID: 29708766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating quality of life in a headache referral population based on Migraine disability assessment scale and headache impact test.
    Togha M; Seyed-Ahadi M; Jafari E; Vahabi Z; Naderi-Behdani F; Nasergivehchi S; Haghighi S; Ghorbani Z; Farham F; Paknejad SMH; Rafiee P
    Curr J Neurol; 2020 Apr; 19(2):76-84. PubMed ID: 38011406
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of validity and reliability of the Migraine disability assessment (MIDAS) versus headache impact test (HIT) in an Iranian population.
    Ghorbani A; Chitsaz A
    Iran J Neurol; 2011; 10(3-4):39-42. PubMed ID: 24250844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab.
    Blumenfeld A; Ettrup A; Hirman J; Ebert B; Cady R
    BMC Neurol; 2022 Jul; 22(1):251. PubMed ID: 35804294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
    J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.
    Buse D; Manack A; Serrano D; Reed M; Varon S; Turkel C; Lipton R
    Headache; 2012 Jan; 52(1):3-17. PubMed ID: 22106869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yoga as an Adjuvant therapy in management of migraine- An open label randomised trial.
    Kumari S; Dhar M; Pathania M; Kumar N; Kulshrestha P; Singh A
    J Family Med Prim Care; 2022 Sep; 11(9):5410-5416. PubMed ID: 36505553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reliability and validity of Hindi translation of the migraine disability assessment and headache impact test-6 questionnaires.
    Juyal R; Verma R; Garg RK; Shukla R; Agarwal A; Singh MK
    Ann Indian Acad Neurol; 2010 Oct; 13(4):276-83. PubMed ID: 21264136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of chiropractic spinal manipulative therapy for migraine.
    Tuchin PJ; Pollard H; Bonello R
    J Manipulative Physiol Ther; 2000 Feb; 23(2):91-5. PubMed ID: 10714533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of spinal manipulation for chronic headache: a systematic review.
    Bronfort G; Assendelft WJ; Evans R; Haas M; Bouter L
    J Manipulative Physiol Ther; 2001 Sep; 24(7):457-66. PubMed ID: 11562654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levetiracetam in Compare to Sodium Valproate for Prophylaxis in Chronic Migraine Headache: A Randomized Double-Blind Clinical Trial.
    Kashipazha D; Ghadikolaei HS; Siavashi M
    Curr Clin Pharmacol; 2017; 12(1):55-59. PubMed ID: 28356053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
    J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial.
    Khani S; Hejazi SA; Yaghoubi M; Sharifipour E
    J Headache Pain; 2021 Apr; 22(1):21. PubMed ID: 33827421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine.
    di Cola FS; Bolchini M; Caratozzolo S; Ceccardi G; Cortinovis M; Liberini P; Rao R; Padovani A
    Neurol Int; 2023 Feb; 15(1):273-284. PubMed ID: 36810472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.